Evidence map›Paper›PMID 38556557›Full record

ArticleMolecular psychiatry2024

Genetic contribution to disease-course severity and progression in the SUPER-Finland study, a cohort of 10,403 individuals with psychotic disorders.

Anders Kämpe, Jaana Suvisaari, Markku Lähteenvuo, Tarjinder Singh, Ari Ahola-Olli, Lea Urpa, Willehard Haaki, Jarmo Hietala, Erkki Isometsä, Tuomas Jukuri and 17 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 9 institutions in 3 countries.

Anders KämpeInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. anders.kampe@helsinki.fi.ORCID 0000-0002-1829-3855
Jaana SuvisaariNational Institute for Health and Welfare, Department of Mental Health and Substance Abuse Services, Helsinki, Finland.ORCID 0000-0001-7167-0990
Markku LähteenvuoInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7244-145X
Tarjinder SinghBroad Institute, Stanley Center for Psychiatric Research, Cambridge, MA, USA.
Ari Ahola-OlliInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Lea UrpaInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID 0000-0002-8712-3518
Willehard HaakiDepartment of Psychiatry, University of Turku, Turku, Finland.
Jarmo HietalaDepartment of Psychiatry, University of Turku, Turku, Finland.
Erkki IsometsäDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tuomas JukuriDepartment of Psychiatry, Oulu University Hospital, Oulu, Finland.
Olli KampmanFaculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Tuula KieseppäHospital District of Helsinki and Uusimaa, Helsinki, Finland.
Kaisla LahdensuoUniversity of Helsinki, Helsinki, Finland.
Jouko LönnqvistDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Teemu MännynsaloDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Tiina PaunioDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-5560-0666
Jussi Niemi-PynttäriDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Kimmo SuokasTampere University, Tampere, Finland.ORCID 0000-0001-6296-6343
Annamari Tuulio-HenrikssonDepartment of Psychology and Logopedics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Juha VeijolaDepartment of Psychiatry, Oulu University Hospital, Oulu, Finland.
Asko WegeliusDepartment of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
SUPERFinland-Researchers
Mark DalyInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
Jacob TaylorHarvard Medical School, Department of Medicine, Boston, USA.
Kenneth S KendlerVirginia Institute of Psychiatric and Behavioral Genetics, Richmond, VA, USA.ORCID 0000-0001-8689-6570
Aarno PalotieInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.ORCID 0000-0002-2527-5874
Olli PietiläinenBroad Institute, Stanley Center for Psychiatric Research, Cambridge, MA, USA.ORCID 0000-0003-4387-1861
University of Helsinki · FIBroad Institute · USUniversity of Turku · FIFinnish Institute for Health and Welfare · FIOulu University Hospital · FIHarvard University · USHospital District of Helsinki and Uusimaa · FITampere University · FIUniversity of Eastern Finland · FI

Funding

Large Scale Sequencing and Analysis of GenomesU54HG003067 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GABRIEL, STACEY, LANDER, ERIC S · 2004 to 2015
$568.6M
Center for Common Disease GeneticsUM1HG008895 · NHGRI · BROAD INSTITUTE, INC. · PI DALY, MARK JOSEPH, GABRIEL, STACEY · 2016 to 2020
$111.2M
3/3-Identifying regulatory mutations that influence neuropsychiatric diseaseU01MH105669 · NIMH · BROAD INSTITUTE, INC. · PI DALY, MARK JOSEPH · 2014 to 2018
$4.5M
NHGRI NIH HHS U54 HG003067NHGRI NIH HHS UM1 HG008895NIMH NIH HHS U01 MH105669Svenska Sällskapet för Medicinsk Forskning (Swedish Society for Medical Research) PD20-0190
6 · The paper itself

Abstract

Genetic factors contribute to the susceptibility of psychotic disorders, but less is known how they affect psychotic disease-course development. Utilizing polygenic scores (PGSs) in combination with longitudinal healthcare data with decades of follow-up we investigated the contributing genetics to psychotic disease-course severity and diagnostic shifts in the SUPER-Finland study, encompassing 10 403 genotyped individuals with a psychotic disorder. To longitudinally track the study participants' past disease-course severity, we created a psychiatric hospitalization burden metric using the full-coverage and nation-wide Finnish in-hospital registry (data from 1969 and onwards). Using a hierarchical model, ranking the psychotic diagnoses according to clinical severity, we show that high schizophrenia PGS (SZ-PGS) was associated with progression from lower ranked psychotic disorders to schizophrenia (OR = 1.32 [1.23-1.43], p = 1.26e-12). This development manifested already at psychotic illness onset as a higher psychiatric hospitalization burden, the proxy for disease-course severity. In schizophrenia (n = 5 479), both a high SZ-PGS and a low educational attainment PGS (EA-PGS) were associated with increased psychiatric hospitalization burden (p = 1.00e-04 and p = 4.53e-10). The SZ-PGS and the EA-PGS associated with distinct patterns of hospital usage. In individuals with high SZ-PGS, the increased hospitalization burden was composed of longer individual hospital stays, while low EA-PGS associated with shorter but more frequent hospital visits. The negative effect of a low EA-PGS was found to be partly mediated via substance use disorder, a major risk factor for hospitalizations. In conclusion, we show that high SZ-PGS and low EA-PGS both impacted psychotic disease-course development negatively but resulted in different disease-course trajectories.

Indexed as

Disease ProgressionGenetic Predisposition to DiseaseHospitalizationMultifactorial InheritancePsychotic DisordersSchizophreniaSeverity of Illness IndexAdultCohort StudiesFemaleFinlandGenotypeHumansLongitudinal StudiesMaleMiddle Aged

Identifiers

PMID38556557
PMCPMC11420086
OpenAlexW4393389160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.